Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Southern Illinois University
mi
from
Springfield, IL
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Southern Illinois University
mi
from
Springfield, IL
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Saint John's Mercy Medical Center
mi
from
Saint Louis, MO
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
The Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
University of Pittsburgh
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
City of Hope Medical Center
mi
from
Duarte, CA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
City of Hope Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Loyola University Medical Center
mi
from
Maywood, IL
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated:  9/3/2015
University of Michigan
mi
from
Ann Arbor, MI
MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy
A Phase II Study of MK-2206 in Patients With Advanced Hepatocellular Carcinoma Who Have Failed or Are Intolerant of One Prior Line of Anti-angiogenic Therapy
Status: Enrolling
Updated: 9/3/2015
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)
Status: Enrolling
Updated:  9/9/2015
University of California at San Francisco
mi
from
San Francisco, CA
Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)
Status: Enrolling
Updated: 9/9/2015
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease
Status: Enrolling
Updated:  9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From Metastatic Colon or Rectal Cancer
Phase II Study of Drug-eluting Irinotecan Beads (DEBIRI) in Refractory Metastatic Colorectal Cancer With Liver-only or Liver-predominant Disease
Status: Enrolling
Updated: 9/10/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated:  9/21/2015
Massachusetts General Hospital
mi
from
Boston, MA
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated: 9/21/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated:  9/21/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated: 9/21/2015
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated:  9/21/2015
Brigham and Women's Hosp
mi
from
Boston, MA
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
A Phase II Study of Cabozantinib (XL-184) Monotherapy in Patients With Advanced Cholangiocarcinoma After Progression on First or Second Line Systemic Therapy
Status: Enrolling
Updated: 9/21/2015
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
24hr Imaging Of HCC After EOVIST
Pilot Study of Delayed, 24 Hour Imaging of Hepatocellular Carcinoma Following the Administration of the Hepatobiliary MRI Contrast Agent Gadolinium Ethoxybenzyl Dimeglumine (Eovist)
Status: Enrolling
Updated:  9/22/2015
Massachusetts General Hospital
mi
from
Boston, MA
24hr Imaging Of HCC After EOVIST
Pilot Study of Delayed, 24 Hour Imaging of Hepatocellular Carcinoma Following the Administration of the Hepatobiliary MRI Contrast Agent Gadolinium Ethoxybenzyl Dimeglumine (Eovist)
Status: Enrolling
Updated: 9/22/2015
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Agajanian Institute Of Hematology And Oncology
mi
from
Downey, CA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Agajanian Institute Of Hematology And Oncology
mi
from
Downey, CA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Sharp Clinical Oncology Research
mi
from
San Diego, CA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Sharp Clinical Oncology Research
mi
from
San Diego, CA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
James Graham Brown Cancer Center
mi
from
Louisville, KY
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
3912 Taubman Center
mi
from
Ann Arbor, MI
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
3912 Taubman Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Univ Of Ark For Med Sci
mi
from
Little Rock, AR
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Univ Of Ark For Med Sci
mi
from
Little Rock, AR
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Va Ct Healthcare System
mi
from
West Haven, CT
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Va Ct Healthcare System
mi
from
West Haven, CT
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Medical Specialists Of Palm Beaches
mi
from
Lake Worth, FL
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Medical Specialists Of Palm Beaches
mi
from
Lake Worth, FL
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Mcguire Dvamc
mi
from
Richmond, VA
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Mcguire Dvamc
mi
from
Richmond, VA
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
University of Wisconsin
mi
from
Madison, WI
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
University of Wisconsin
mi
from
Madison, WI
Click here to add this to my saved trials
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  9/23/2015
Local Institution
mi
from
Caba,
First Line Hepato Cellular Carcinoma (HCC)
A Randomized, Double-blind, Multi-center Phase III Study of Brivanib Versus Sorafenib as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 9/23/2015
Local Institution
mi
from
Caba,
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
City of Hope National Medical Center
mi
from
Duarte, CA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Harbor-Ucla Medical Center
mi
from
Los Angeles, CA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Harbor-Ucla Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Christiana Care Health Services, Inc
mi
from
Newark, DE
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Christiana Care Health Services, Inc
mi
from
Newark, DE
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
University of Miami Miller School of Medicine
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
University of Chicago
mi
from
Chicago, IL
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Wayne State University
mi
from
Detroit, MI
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Wayne State University
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
The Cancer Center, Hackensack University Medical Center
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Duke Univ Med Ctr
mi
from
Durham, NC
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Albert Einstein Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
University of Texas Southwestern
mi
from
Dallas, TX
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
University of Texas Southwestern
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated:  9/23/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer
A Phase II Open Label Study of Brivanib (BMS582664), Administered Orally At A Dose of 800 mg Daily In Subjects With Unresectable, Locally Advanced or Metastatic Hepatocellular Carcinoma Who Have Received Either No Prior Systemic Therapy or One Prior Regimen of Angiogenesis Inhibitor Therapy
Status: Enrolling
Updated: 9/23/2015
Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials